Sleep Disorders Therapeutics
1. Belsomra patent expiration
Treatment: Treatment of insomnia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11980623 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(7 years from now) | |
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
| M(M-253) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Dosage: TABLET
More Information on Dosage
BELSOMRA family patents
2. Dayvigo patent expiration
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| US10702529 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| US11026944 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Dosage: TABLET
More Information on Dosage
DAYVIGO family patents
3. Hetlioz patent
expiration
Treatment: Treatment of non-24-hour sleep-wake disorder; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon; Treatment of non-24-hour sleep-wake disorder by avoiding...
HETLIOZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(3 years ago) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US12049457 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785492 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(9 years from now) | |
| US12201604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(8 years from now) | |
| US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(15 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(9 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(9 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11918557 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11918556 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Apr, 2033
(7 years from now) | |
| US11826339 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Dosage: CAPSULE
How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage
HETLIOZ family patents
4. Lunesta patent expiration
Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6864257 | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2012
(13 years ago) | |
| US6444673 | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Feb, 2014
(11 years ago) | |
|
US6444673 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2014
(11 years ago) | |
|
US6864257 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Mar, 2013
(12 years ago) | |
|
US7381724 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
Jul, 2012
(13 years ago) | |
|
US6319926 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Jul, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Oct 10, 2015 |
| Pediatric Exclusivity(PED) | Apr 10, 2016 |
Drugs and Companies using ESZOPICLONE ingredient
Market Authorisation Date: 15 December, 2004
Dosage: TABLET
How can I launch a generic of LUNESTA before it's drug patent expiration?
More Information on Dosage
LUNESTA family patents
5. Neupro patent expiration
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of r...
NEUPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6884434 | UCB INC | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar, 2021
(4 years ago) | |
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(2 years ago) | |
| US7413747 | UCB INC | Transdermal therapeutic system for treating Parkinsonism |
Mar, 2019
(6 years ago) | |
| US6699498 | UCB INC | Transdermal therapeutic systems having improved stability and their production |
Nov, 2020
(5 years ago) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(1 year, 7 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(a month ago) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(6 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-646) | Apr 02, 2015 |
| New Indication(I-647) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of NEUPRO before it's drug patent expiration?
More Information on Dosage
NEUPRO family patents
6. Quviviq patent expiration
Treatment: Treatment of insomnia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(7 years from now) | |
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
| M(M-200) | Sep 30, 2027 |
| M(M-310) | Sep 30, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Dosage: TABLET
More Information on Dosage
QUVIVIQ family patents
7. Rozerem patent expiration
Treatment: Method of treating a biological rhythm disorder, such as insomnia; Method of treating insomnia characterized by difficulty with sleep onset
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098866 | TAKEDA PHARMS USA | Pharmaceutical preparation containing copolyvidone |
Nov, 2021
(4 years ago) | |
| US6034239 | TAKEDA PHARMS USA | Tricyclic compounds, their production and use |
Jul, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Oct 20, 2011 |
Drugs and Companies using RAMELTEON ingredient
Market Authorisation Date: 22 July, 2005
Dosage: TABLET
How can I launch a generic of ROZEREM before it's drug patent expiration?
More Information on Dosage
ROZEREM family patents
8. Sunosi patent expiration
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness in a breast-feeding pa...
SUNOSI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12384743 | AXSOME MALTA | NA |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(5 years from now) | |
| US12209059 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12390419 | AXSOME MALTA | NA |
Sep, 2037
(11 years from now) | |
| US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US12263145 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US12318362 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12194016 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(13 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
9. Xyrem patent expiration
Treatment: Method of treating cataplexy in patients with narcolepsy; Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Method of treating exce...
XYREM's oppositions filed in EPO
XYREM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9539330 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
| US8952062 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US8589182 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
|
US8731963 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
| US8263650 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
|
US6780889 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(5 years ago) | |
|
US7262219 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(5 years ago) | |
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 24 days ago) | |
|
US7895059 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
|
US8457988 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
| US7262219 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(5 years ago) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 24 days ago) | |
| US8859619 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
|
US8589182 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
|
US7851506 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8263650 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8324275 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8859619 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8952062 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
| US9539330 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US8457988 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US8324275 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 24 days ago) | |
| US7895059 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US7851506 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US7765107 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
| US7765106 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
| US6780889 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(5 years ago) | |
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US11986446 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Dosage: SOLUTION
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents